Synta Pharmaceuticals, which is developing drugs for chronic inflammatory diseases and cancer, filed the terms for its IPO on Tuesday. The Lexington, MA-based company plans to offer 6 million shares at a range of $14-$16. The deal has a proposed market cap of $500 million. Bear Stearns and Lehman Brothers are managing the deal which is expected to price the week of February 5th.
